Replication-associated base excision repair/single-strand break repair regulates PARG inhibitor response via the PRMT1/PRMT5/ATR axis
NAR Cancer · 2025
DOI: 10.1093/narcan/zcaf057 ↗Kurz gefasst
Fachartikel in der Zeitschrift NAR Cancer, 2025. Verfasst von Md Ibrahim und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology & Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, United States. Hauptthemen laut MEDLINE: Protein-Arginine N-Methyltransferases, DNA Repair, Ataxia Telangiectasia Mutated Proteins, Repressor Proteins. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 159 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIEHS NIH HHS, NCI NIH HHS, NIA NIH HHS.
Abstract (Originalsprache)
Poly(ADP-ribose) polymerases 1 and 2 (PARP1/PARP2), and poly(ADP-ribose) glycohydrolase (PARG), modulate the level of poly(ADP-ribose) (PAR), a post-translational protein modification, in response to DNA damage or replication stress. Here, we find that replication-dependent and PARP1/PARP2-mediated PARylation recruits the base excision repair (BER)/single-strand break repair (SSBR) scaffold protein XRCC1 and the associated factors DNA polymerase β (POLB), aprataxin (APTX), and DNA ligase isoform 3 (LIG3). Further, these BER/SSBR proteins promote resistance to inhibitors of PARP1/PARP2 and PARG, as loss of these proteins sensitizes glioblastoma and ovarian cancer cells to each. In addition, depletion of these replication-associated BER/SSBR factors leads to enhanced PAR levels and PARG inhibitor-induced activation of the ATR/CHK1 S-phase checkpoint kinases. Both PARG inhibition and ATR inhibition lead to elevated ATM- and DNA-PK-dependent KAP1 phosphorylation. In turn, inhibition of either ATR or CHK1 enhances the cellular response to PARG inhibitors. Finally, inhibition of the ATR regulators PRMT1 or PRMT5 synergizes with PARG inhibition, implicating replication-associated BER/SSBR and PARylation in the activation of the PRMT1/PRMT5/ATR axis. This study highlights the role of BER/SSBR in protecting the cell during S-phase to suppress PARylation-induced checkpoint activation, which may suggest a potential intervention strategy for PARG inhibitor-resistant tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology & Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, United States.
- Department of Pathology and Laboratory Medicine, Warren Alpert Medical School & Legorreta Cancer Center, Brown University, Providence, RI 02912, United States.
ORCID-Profile: Md Ibrahim, Wynand P Roos, Robert W Sobol
Förderung
- NIEHS NIH HHS
- NCI NIH HHS
- NIA NIH HHS
- NIH
- NSF
- Legoretta Cancer Center Endowment Fund
- Breast Cancer Research Foundation of Alabama
- Mitchell Cancer Institute Molecular & Metabolic Oncology Program Development Fund
Zitieren
APA
Ibrahim, M., Roos, W. P., Schwartz, J. C., Khan, M. M., Al-Rahahleh, R. Q., Beers, L. A., Pearson, C. R., Langham, K. T., Boyang, L., Clark, J., Hayat, F., Fang, Q., Koczor, C. A., Migaud, M. E., & Sobol, R. W. (2025). Replication-associated base excision repair/single-strand break repair regulates PARG inhibitor response via the PRMT1/PRMT5/ATR axis. NAR Cancer. https://doi.org/10.1093/narcan/zcaf057
Vancouver
Ibrahim M, Roos WP, Schwartz JC, Khan MM, Al-Rahahleh RQ, Beers LA, et al. Replication-associated base excision repair/single-strand break repair regulates PARG inhibitor response via the PRMT1/PRMT5/ATR axis. NAR Cancer. 2025. doi:10.1093/narcan/zcaf057
BibTeX
@article{Ibrahim2025,
author = {Ibrahim, Md and Roos, Wynand P and Schwartz, Jacob C and Khan, Md Maruf and Al-Rahahleh, Rasha Q and Beers, Libby A and Pearson, Charlotte R and Langham, Kahrie T and Boyang, Louis and Clark, Jennifer and Hayat, Faisal and Fang, Qingming and Koczor, Christopher A and Migaud, Marie E and Sobol, Robert W},
title = {Replication-associated base excision repair/single-strand break repair regulates PARG inhibitor response via the PRMT1/PRMT5/ATR axis},
journal = {NAR Cancer},
year = {2025},
doi = {10.1093/narcan/zcaf057}
}
EUVIMED